Download PDF
Thromb Haemost 1978; 40(02): 423-427
DOI: 10.1055/s-0038-1648676
Original Article
Schattauer GmbH Stuttgart

The Effects of a Combined Alpha- and Beta-Blocking Drug, Labetalol, on Some Aspects of Platelet Function

Knut Lote
The Dept. of International Medicine, Institute of Clinical Medicine, University of Tromsø, N-9012 Tromsø, Norway
,
Birgit J Svenson
The Dept. of International Medicine, Institute of Clinical Medicine, University of Tromsø, N-9012 Tromsø, Norway
,
Unni Ånstad
The Dept. of International Medicine, Institute of Clinical Medicine, University of Tromsø, N-9012 Tromsø, Norway
,
Arne Nordøy
The Dept. of International Medicine, Institute of Clinical Medicine, University of Tromsø, N-9012 Tromsø, Norway
› Author Affiliations
Further Information

Publication History

Received 29 September 1977

Accepted 30 January 1978

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effects of the combined alpha- and beta-adrenoreceptor blocking agent labetalol on human blood platelets as estimated by platelet aggregation, platelet count, bleeding time and platelet factor 3 activity were studied in 5 patients. The drug reduced adrenaline - induced platelet aggregation in vitro. However, it did not influence the above platelet function test in therapeutic plasma concentrations in vivo.

 

  • References

  • 1 Born GV R. 1962; Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927
    PubMedGoogle Scholar
  • 2 Brittain RT, Levy GP. 1976; A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoreceptor-blocking rug. British Journal of Clinical Pharmacology 3 Supplement (Suppl. 03) 681
    PubMedGoogle Scholar
  • 3 Bruyere MDE, Bellenot C, Sokal G. 1974; Electronic platelet counting after isopycnic differential centrifugation. A simple, rapid, and accurate method Thrombosis Diathesis et Haemorrhagica 32: 232
    PubMedGoogle Scholar
  • 4 Frick MH, Porsti P. 1976; Combined alpha- and beta-adrenoreceptor blockade with labetalol in hypertension. British Medical Journal 1: 1046
    CrossrefPubMedGoogle Scholar
  • 5 Harrison MJ G, Emmons PR, Mitchell JR A. 1977; The variability of human platelet aggregation. Journal of Atherosclerosis Research 7: 197
    PubMedGoogle Scholar
  • 6 Holmsen H, Day HJ, Storm E. 1969; Adenine nucleotide metabolism of blood platelets. Subcellular localization of nucleotide pools with different functions in the platelet release reaction Biochimica et biophysica acta 186: 254
    CrossrefPubMedGoogle Scholar
  • 7 IVY AC, Nelson D, Bucher G. 1940; The standardization of certain factors in the cutaneous “venostasis” bleeding time technique. Journal of Laboratory and Clinical Medicine 26: 1812
    PubMedGoogle Scholar
  • 8 Martin LE, Hopkins R, Bland R. 1976; Metabolism of labetalol by animals and man. British Journal of Clinical Pharmacology 3 Suppl (Suppl. 03) 695
    PubMedGoogle Scholar
  • 9 Mills DC B, Roberts GC K. 1967; Effects of adrenaline on human blood platelets. Journal of Physiology 193: 443
    CrossrefPubMedGoogle Scholar
  • 10 Nathan I, Dvilansky A, Sage J, Korczyn AD. 1977; Effects of propranolol and pindolol on platelet aggregation and serotonin release. Life Sciences 20: 407
    CrossrefPubMedGoogle Scholar
  • 11 Nordoy A, Lund S. 1968; Platelet factor 3 activity, platelet phospholipids and their fatty acid and aldehyde pattern in normal male subjects. Scandinavian Journal of Clinical and Laboratory Investigation 22: 328
    CrossrefPubMedGoogle Scholar
  • 12 O’Brien JR. 1963; Some effects of adrenaline and anti-adrenaline compounds on platelets in vitro and in vivo. Nature 200: 763
    CrossrefPubMedGoogle Scholar
  • 13 Weksler B, Pink J. 1975; Propranolol as a modifier of platelet function by membrane action. Clinical Research 23: 284
    PubMedGoogle Scholar